Base de datos : ins
Búsqueda : RESISTENCIA A MEDICAMENTOS [Descritor de assunto]
Referencias encontradas : 9 [refinar]
Mostrando: 1 .. 9   en el formato [Detallado]

página 1 de 1

  1 / 9 ins  
              next record last record
selecciona
para imprimir
Texto completo
Id:8797
Autor:Sacsaquispe Contreras, Rosa.
Título:Reunión regional de vigilancia de la resistencia bacteriana a los antibióticos 2009. Lima, Perú^ies / Meeting regional surveillance of bacterial resistance to antibiotics 2009 Lima, Peru
Fuente:Bol. Inst. Nac. Salud;16(1/2):15-17, ene.-feb. 2010. .
Descriptores:Farmacorresistencia Bacteriana
Vigilancia de Productos Comercializados
Resistencia a Medicamentos
Perú
Límites:Humanos
Medio Electrónico:http://www.ins.gob.pe/RepositorioAPS/0/0/par/BOLETIN_INS_2010/boletin%20Ene_Feb_2010.pdf / es
Localización:PE14.1


  2 / 9 ins  
              first record previous record next record last record
selecciona
para imprimir
Texto completo
Id:8771
Autor:Llanos-Zavalaga, Luis; Velásquez-Hurtado, José; García, Patricia; Gottuzzo, Eduardo.
Título:Tuberculosis y salud pública: ¿derechos individuales o derechos colectivos?^ies / Tuberculosis and public health: ¿individual rights or collective rights?
Fuente:Rev. peru. med. exp. salud publica;29(2):259-264, abr.-jun. 2012. .
Resumen:La tuberculosis (TB) persiste como un problema de salud pública de grandes dimensiones en el Perú. La aparición de cepas fármaco-resistentes ha dificultado su control y puesto en cuestionamiento las medidas que actualmente se toman para la prevención y control. Un análisis desde los “determinantes sociales” relacionados con TB, confluyen hacia un tratamiento irregular, lo que ocasiona su persistencia y desarrollo de fármaco-resistencia. El objetivo es identificar el rol del Estado en el tratamiento de pacientes con TB; reconocer las dificultades del paciente en el cumplimiento del tratamiento, lo cual repercute en la salud colectiva; y discutir sus alternativas de manejo, basados en los derechos del paciente y la sociedad. La literatura internacional muestra experiencias límite entre los derechos individuales y colectivos, pero respaldado por políticas sanitarias y su legislación. En el Perú se requiere una nueva mirada que garantice la salud de la población sin vulnerar los derechos individuales(AU)^ies.
Descriptores:Tuberculosis/transmisión
Salud Pública/educación
Resistencia a Medicamentos/efectos de drogas
 Derechos Humanos
 Perú
Límites:Humanos
Medio Electrónico:http://www.ins.gob.pe/insvirtual/images/artrevista/pdf/rpmesp2012.v29.n2.a16.pdf / es
Localización:PE14.1


  3 / 9 ins  
              first record previous record next record last record
selecciona
para imprimir
Id:8404
Autor:Organización Mundial de la Salud*.
Título:Comité de expertos de la OMS en paludismo^ies Expert Committee on Malaria-
Fuente:Ginebra; Organización mundial de la Salud; 2000. 85 p. ^bgraf.
Descriptores:Malaria/quimioterapia
Malaria/prevención & control
Reforma de la Atención de Salud
Resistencia a Medicamentos
 DDT/farmacología
Localización:PE14.4; CH-00332


  4 / 9 ins  
              first record previous record next record last record
selecciona
para imprimir
Id:8336
Autor:Karahan, Z. C; Akar, N
Título:Restriction endonuclease analysis as a solution for determining rifampin resistance mutations by automated DNA sequencing in heteroresistant Mycobacterium tuberculosis strains^ien ..-
Fuente:Larchmont; Mary Ann Liebert; 2005. 137-40 p. ^bgraf, ^bilus.
Resumen:Rifampin resistance in Mycobacterium tuberculosis is mainly due to a small number of mutations in the rpoB gene coding for the beta subunit of RNA polymerase. Heteroresistance, which is defined as a mixture of wildtype and resistant subpopulations in the same culture, can influence the sensitivity of molecular tests for determining drug resistance by leading to false negative or indeterminable results. In our laboratory, we identified one heteroresistant strain during sequencing of the rpoB gene mutations, which are responsible for Rifampin resistance in M. tuberculosis. The sequence analysis of this isolate demonstrated the mixture of different strains, and the exact nature of the mutation could not be determined. In order to solve this problem, the possible mutation site was digested with Tsp509I restriction endonuclease, which made us separate the different strains. Sequencing of the separated mutated product revealed the mutation responsible for Rifampin resistance. From this result, we propose that, when the suggested mutation site creates and/or deletes a restriction endonuclease recognition site in heteroresistant populations, restriction endonuclease analysis can be used to ease the determination of resistance mutations by sequencing. (AU)^ien.
Descriptores:Rifampin
Tuberculosis
Mycobacterium tuberculosis
Resistencia a Medicamentos
Límites:Humanos
Localización:PE14.1


  5 / 9 ins  
              first record previous record next record last record
selecciona
para imprimir
Id:8335
Autor:Ling, D. I; Zwerling, A. A; Pai, M
Título:GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis^ien ..-
Fuente:Copenhagen; Society and Munksgaard; 2008. 1165-74 p. ^btab, ^bgraf.
Resumen:The global extensively drug-resistant tuberculosis (TB) response plan calls for implementation of rapid tests to screen patients at risk of drug-resistant TB. Currently, two line probe assays exist, the INNO-LiPA(R)Rif.TB assay (Innogenetics, Ghent, Belgium) and the GenoType MTBDR assay (Hain LifeScience GmbH, Nehren, Germany). While LiPA studies have been reviewed, the accuracy of GenoType assays has not been systematically reviewed. The present authors carried out a systematic review and used meta-analysis methods appropriate for diagnostic accuracy. After the literature searches, 14 comparisons for rifampicin and 15 comparisons for isoniazid were identified in 10 articles that used GenoType MTBDR assays. Accuracy results were summarised in forest plots and pooled using bivariate random-effects regression. The pooled sensitivity (98.1 percent, 95 percent confidence interval (CI) 95.9-99.1) and specificity (98.7 percent, 95 percent CI 97.3-99.4) estimates for rifamp percentcin resistance were very high and consistent across all subgroups, assay versions and specimen types. The accuracy for isoniazid was variable, with lower sensitivity (84.3 percent, 95 percent CI 76.6-89.8) and more inconsi percenttent than specificity (99.5 percent, 95 percent CI 97.5-99.9). GenoType MDTBR assays demonstrate excellent accuracy for rifampicin resistance, even when used on clinical specimens. While specificity is excellent for isoniazid, sensitivity estimates were modest and variable. Together with data from demonstration projects, the meta-analysis provides evidence for policy making and clinical practice. (AU)^ien.
Descriptores:Resistencia a Medicamentos
Tuberculosis/diagnóstico
Límites:Humanos
Localización:PE14.1


  6 / 9 ins  
              first record previous record next record last record
selecciona
para imprimir
Texto completo
Id:8290
Autor:Walensky, R. P
Título:HIV drug resistance surveillance for prioritizing treatment in resource-limited settings^ies ..-
Fuente:Massachusetts; Lippincott Williams y Wilkins; 2007. 973-982 p. ^btab, ^bgraf.
Resumen:BACKGROUND: Sentinel testing programs for HIV drug resistance in resource-limited settings can inform policy on antiretroviral therapy (ART) and drug sequencing.OBJECTIVE: : To examine the value of resistance surveillance in influencing recommendations toward effective and cost-effective sequencing of ART regimens.METHODS: A state-transition model of HIV infection was adapted to simulate clinical care in Cote d'Ivoire and evaluate the incremental cost-effectiveness of (1) no ART; (2) ART beginning with a non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimen followed by a boosted protease inhibitor (PI)-based regimen; and (3) ART beginning with a boosted PI-based regimen followed by an NNRTI-based regimen.RESULTS: At a 5 percent prevalence of NNRTI resistance, a strategy that started with a PI-based regimen had a smaller health benefit and higher cost-effectiveness ratio than a strategy that started with an NNRTI-based regimen (cost-effectiveness ratio dollares 910/year of life saved). Results consistently favored initiation with an NNRTI-based regimen, regardless of the population prevalence of NNRTI resistance (up to 76 percent) and the efficacy of an NNRTI-based regimen in the setting of resistance. The most influential parameters on the cost-effectiveness of sequencing strategies were boosted PI-based regimen costs and the efficacy of this regimen when used as second-line therapy.CONCLUSIONS: Drug costs and treatment efficacies, but not NNRTI resistance levels, were most influential in determining optimal HIV drug sequencing in Cote d'Ivoire. Results of surveillance for NNRTI resistance should not be used as a major guide to treatment policy in resource-limited settings. (AU)^ien.
Descriptores:VIH
Resistencia a Medicamentos
África
Límites:Humanos
Medio Electrónico:http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2367006/pdf/nihms45657.pdf / en
Localización:PE14.1


  7 / 9 ins  
              first record previous record next record last record
selecciona
para imprimir
Texto completo
Id:8049
Autor:Ascencios, Luis.
Título:Tuberculosis: resultados de la vigilancia de la resistenciaa drogas antituberculosas^ies / Tuberculosis: results of surveillance of resistance
Fuente:Bol. Inst. Nac. Salud (Perú);11(3/4):73-73, mar.-abr. 2005. ^bgraf.
Descriptores:Tuberculosis/epidemiología
Tuberculosis/prevención & control
Vigilancia Epidemiológica
Resistencia a Medicamentos
Perú
Límites:Humanos
Medio Electrónico:http://www.ins.gob.pe/RepositorioAPS/0/0/par/BOLETIN_2005/Boletin%20Marzo%20Abril%202005.pdf / es
Localización:PE14.1


  8 / 9 ins  
              first record previous record next record last record
selecciona
para imprimir
Texto completo
Id:8010
Autor:Suárez, Víctor.
Título:Resistencia a los antimicrobianos^ies / Antimicrobial resistance
Fuente:Bol. Inst. Nac. Salud (Perú);13(11/12):216-217, nov.-dic. 2007. .
Descriptores:Resistencia a Medicamentos
Vigilancia Epidemiológica
Medio Electrónico:http://www.ins.gob.pe/RepositorioAPS/0/0/par/BOLINS_13/BOLETIN_NOV%20DIC_2007.pdf / es
Localización:PE14.1


  9 / 9 ins  
              first record previous record
selecciona
para imprimir
Texto completo
Id:7964
Autor:Asencio Solís, Luis; Quispe Torres, Neyda; Mendoza Ticona, Alberto; Leo Hurtado, Elena; Vásquez Campos, Lucy; Jave, Oswaldo; Bonilla, César.
Título:Vigilancia nacional de la resistencia a medicamentos antituberculosos, Perú 2005-2006^ies / National surveillance of TB drug resistance, Peru 2005-2006
Fuente:Bol. Inst. Nac. Salud (Perú);15(7/8):186-187, jul.-agos. 2009. ^bgraf.
Descriptores:Tuberculosis Resistente a Múltiples Medicamentos
Resistencia a Medicamentos
Tuberculosis
Vigilancia Epidemiológica
Programas Nacionales de Salud
Límites:Humanos
Masculino
Femenino
Medio Electrónico:http://www.ins.gob.pe/RepositorioAPS/0/0/par/BOLETIN_INS/boletin_JUL_AGO2009.pdf / es
Localización:PE14.1



página 1 de 1
   


Refinar la búsqueda
  Base de datos : ins Formulario avanzado   
Buscar por : Formulario libre   

    Buscar en el campo  
1  
2
3
 
           



Search engine: iAH v2.6.1 powered by WWWISIS

BIREME/OPS/OMS - Centro Latinoamericano y del Caribe de Información en Ciencias de la Salud